Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 415Magnetic Resonance Spectroscopy 332pembrolizumab 261Biopsy 227Carboplatin 216Cisplatin 179Cyclophosphamide 174Paclitaxel 148Nivolumab 135Gemcitabine 130Radiotherapy 120Dexamethasone 105Bevacizumab 101fludarabine 95Radiation 94Fluorouracil 93Pemetrexed 88Doxorubicin 88Docetaxel 83Rituximab 82venetoclax 81durvalumab 81Oxaliplatin 81Leucovorin 76atezolizumab 68Lenalidomide 66Capecitabine 66Prednisone 65Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × epacadostat × 30 days × Clear all
NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Incyte Corporation

Phase 3 Completed
129 enrolled 13 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡